Insmed's drug Brinsupri has failed to meet its clinical trial goals for treating hidradenitis suppurativa, leading the company to discontinue its development for this condition. Despite this setback, Brinsupri remains projected to achieve blockbuster status for its approved use in treating non-cystic fibrosis bronchiectasis, with potential peak sales estimated at $7.4 billion by 2039.
Insmed's Brinsupri, despite its recent clinical trial failure for hidradenitis suppurativa, remains a promising asset due to its FDA approval for non-cystic fibrosis bronchiectasis, with projected peak sales of $7.4 billion by 2039. This situation highlights the importance of diversifying indications in biotech, as successful approvals in other areas can mitigate setbacks. For those tracking investment opportunities, Brinsupri's potential in bronchiectasis presents a significant revenue driver despite its challenges in other inflammatory disorders.